about
sameAs
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/lLong‐Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta‐Analysis of Placebo‐Controlled TrialsAdjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infectionAdjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials.Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus InfectionOrosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulationGenetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyPublic-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland comparedPhylogenetic approach reveals that virus genotype largely determines HIV set-point viral loadLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensRisk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyThe individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsMajor Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin AmericaCorrection: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing RegimensMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsUpdate of the Swiss guidelines on post-treatment Lyme disease syndrome.Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better.[Antiretroviral therapy].Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study.Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapyImproved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infectionMolecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.Sexually transmitted infections in HIV-infected people in Switzerland: cross-sectional study.Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equalOpportunistic infections: an update.Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosisHigh colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors.Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
P50
Q21128672-3CE9590D-F073-4581-AC82-E594CBCEBD3EQ22242946-BA1845BC-CF09-4FDA-9E3F-ECB760AE2FD1Q24245547-F5574139-02AE-476A-8DFA-AEC2627EBF23Q24815855-62F6ED26-5255-41D7-B939-EE36F0643803Q24815855-B5C2F53F-817B-4576-8E5A-FAA3BD16FBA7Q27477614-7A0D4D1F-AE99-4A68-BABD-39771B12C724Q28266466-93B42A20-6A2E-4A24-B28D-1263E87BADB3Q28269827-28F3252A-75B3-4679-85BB-E1F6D6B99C64Q28473120-C2D78067-6389-42DC-91A8-0B3B2A9F9D8EQ28475652-CAEC322C-6D39-48D7-B41A-5814CA1B44D8Q28485321-0F9AD842-3379-4550-BBA9-8C6226661AF0Q28534394-8F51BA7D-C744-433F-AF2E-3B9F4347EE71Q28534423-DBEADA92-2003-4189-A6B4-A65C4A022DC1Q28536153-CC89811C-6D4B-41A5-A87D-66A6D28DB1BAQ28551909-6EF12236-C18E-4035-924D-3F87FA9AE9AFQ28683189-3C4F208D-A7DA-44CD-A436-D024323D743BQ28728304-C24446F3-D4B5-405E-AC5C-5A3A3C4B97C4Q30240176-7CBF9248-4DC3-4523-A7D4-F0D75A4F6F0EQ30248374-C39CEF4A-EA31-4C21-8156-299971C28793Q30365431-BBA16D3A-6995-4831-B82B-AB7A2A5E5F25Q33410342-56439609-04E1-40BC-9B5D-CC0F69DF2066Q33622785-20F2211F-C69C-4FAD-9A9E-199D9DF88BB1Q33678071-5A39FBD3-1F7E-4408-9701-CD1BD2E3F3EAQ33873614-7B46FCB2-7BF1-42A1-B839-8A8F19AA131BQ33876965-58D332FB-33FF-4FBA-818E-F259862D0325Q34075008-602592AF-665A-4495-9740-8B1998FC65FEQ34109639-585162C9-C7B8-4304-A83C-9E080F7B3F6BQ34113502-6EA7516D-36DC-49CB-BF9C-A7C947D5DE59Q34127697-56BADD7B-8215-405E-B340-D939FEEF6472Q34136227-A64736A1-9E94-465D-A19D-3B4C44202C7AQ34147224-9AAA9307-6F1F-4840-8FEF-F77E92464A74Q34213437-72A70457-F433-4B81-AD7E-B700F705F6E7Q34269641-0B2AD346-B88F-4A5A-81F6-A19667FA6FE2Q34546056-DA64D902-A425-4AD4-B3AF-17CFB84A7BDCQ34603168-57F2DD29-9CE8-4C94-BD4F-F95DFE543506Q34604081-7B4CB912-24B0-452C-86E7-64D902F4E1E3Q34625399-C6B62F4C-DF72-4DB6-B426-F048C9C2E8E0Q34671432-E3E7D143-9FE9-4E14-9D82-8415AB779C1FQ34763589-1A8D183E-BECA-442A-A00B-5DCC5D1D614AQ34772825-7F364B80-4592-498D-8A4C-EE6340B5B8A6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hansjakob Furrer
@ast
Hansjakob Furrer
@en
Hansjakob Furrer
@es
Hansjakob Furrer
@nl
Hansjakob Furrer
@sl
type
label
Hansjakob Furrer
@ast
Hansjakob Furrer
@en
Hansjakob Furrer
@es
Hansjakob Furrer
@nl
Hansjakob Furrer
@sl
prefLabel
Hansjakob Furrer
@ast
Hansjakob Furrer
@en
Hansjakob Furrer
@es
Hansjakob Furrer
@nl
Hansjakob Furrer
@sl
P106
P21
P31
P496
0000-0002-1375-3146